Literature DB >> 25510260

Suboptimal surgery and omission of neoadjuvant therapy for upper rectal cancer is associated with a high risk of local recurrence.

P Bondeven1, S Laurberg, R H Hagemann-Madsen, B Ginnerup Pedersen.   

Abstract

AIM: The aim of the present study was to estimate the risk of local recurrence in an audited cohort of patients, with a particular focus on patients with upper rectal cancer treated by partial mesorectal excision without neoadjuvant therapy.
METHOD: Perioperative clinical data on all patients who underwent mesorectal excision for primary adenocarcinoma of the rectum in the period from 2007 to 2010 were prospectively collected and follow-up data on oncological outcome were retrieved from patient records. Three-year actuarial local recurrence rates were estimated using Kaplan-Meier methods.
RESULTS: Local recurrence was diagnosed in 17 of 247 patients treated with curative intent. The 3-year actuarial local recurrence rate was 7.0% (95% CI 4.0-11.8). The risk of local recurrence was negatively associated with tumour stage (P = 0.015), an involved circumferential resection margin (P = 0.007) and tumour height (P = 0.044). The local recurrence rate at 3 years was 13.5% after partial mesorectal excision, 2.9% following total mesorectal excision and 5.7% after extralevator abdominoperineal excision (P = 0.032).
CONCLUSION: Tumour stage and an involved circumferential resection margin were the most important predictors of local recurrence. For cancer of the upper rectum, partial mesorectal excision was associated with a high risk of local recurrence. Colorectal Disease
© 2014 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  Rectal cancer; local recurrence; neoadjuvant therapy; residual mesorectum

Mesh:

Year:  2015        PMID: 25510260     DOI: 10.1111/codi.12869

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  6 in total

1.  Re: staying on target-reply to comments by Loyal et al.

Authors:  J D Foster; N J Smart; N K Francis
Journal:  Tech Coloproctol       Date:  2015-01-23       Impact factor: 3.781

2.  Neoadjuvant chemoradiation improves oncologic outcomes in low and mid clinical T3N0 rectal cancers.

Authors:  Olga A Lavryk; Elena Manilich; Michael A Valente; Arshiya Miriam; Emre Gorgun; Matthew F Kalady; Sherief Shawki; Conor P Delaney; Scott R Steele
Journal:  Int J Colorectal Dis       Date:  2019-11-27       Impact factor: 2.571

3.  Distinct Prognosis of High Versus Mid/Low Rectal Cancer: a Propensity Score-Matched Cohort Study.

Authors:  Lv-Jia Cheng; Jian-Hui Chen; Song-Yao Chen; Zhe-Wei Wei; Long Yu; Shao-Pu Han; Yu-Long He; Zi-Hao Wu; Chuang-Qi Chen
Journal:  J Gastrointest Surg       Date:  2019-01-07       Impact factor: 3.452

Review 4.  Required distal mesorectal resection margin in partial mesorectal excision: a systematic review on distal mesorectal spread.

Authors:  A A J Grüter; A S van Lieshout; S E van Oostendorp; J C F Ket; M Tenhagen; F C den Boer; R Hompes; P J Tanis; J B Tuynman
Journal:  Tech Coloproctol       Date:  2022-08-29       Impact factor: 3.699

5.  Impact of a multidisciplinary training programme on outcome of upper rectal cancer by critical appraisal of the extent of mesorectal excision with postoperative MRI.

Authors:  P Bondeven; S Laurberg; R H Hagemann-Madsen; B G Pedersen
Journal:  BJS Open       Date:  2019-12-13

Review 6.  Applications of Artificial Intelligence in Screening, Diagnosis, Treatment, and Prognosis of Colorectal Cancer.

Authors:  Hang Qiu; Shuhan Ding; Jianbo Liu; Liya Wang; Xiaodong Wang
Journal:  Curr Oncol       Date:  2022-03-07       Impact factor: 3.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.